Clareo Health | An Observational Study to Learn More About the Impact of Gadoxetate Sodium-Enhanced Magnetic Resonance Imaging (EOB-MRI) When Used to Diagnose the Spread of Cancer From the Pancreas to the Liver in Japanese People Under Real-World Conditions
An Observational Study to Learn More About the Impact of Gadoxetate Sodium-Enhanced Magnetic Resonance Imaging (EOB-MRI) When Used to Diagnose the Spread of Cancer From the Pancreas to the Liver in Japanese People Under Real-World Conditions
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bayer
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients having at least one confirmed diagnosis of pancreatic cancer (identified by ICD-10 diagnosis code C25.x, without a suspicious diagnosis flag) during the patient selection period
Patients having at least one active treatment record after the 1st confirmed diagnosis of pancreatic cancer
Patients 18 years of age or older at the index date
Patients having any recorded CE-CT or EOB-MRI or MRI without EOB record during the baseline period
* EOB-MRI stands for enhanced liver MRI using gadoxetate sodium as the contrast agent. In this type of MRI, gadoxetate sodium is used as a contrast agent in the visualization of the liver tumor.
* EOB-MRI group will include patients who underwent EOB-MRI during the baseline period.
* Non-EOB-MRI group will include patients who underwent CE-CT or MRI with contrast agent other than the gadoxetate sodium during the baseline period.
* MRI, CE-CT and contrast agents are identified by using the nine-digit Japanese receipt code specified in the separate code list
You may not be if
Patients with no confirmed diagnosis of pancreatic cancer (ICD-10 diagnosis code C25.x) in the below category of the disease name in the discharge summary until the 1st discharge date after the index date:
* "ICD-10 code of disease name which input the most medical resources"
* "ICD-10 name of disease behind hospitalization"
Patients with no active treatment within 3 months (90 days) from the con-firmed pancreatic cancer diagnosis date
Patients with no medical record in the MDV database within 1 month (30 days) from the index date
